New Teva Representative Joins Mesoblast Board Of Directors
News Oct 22, 2012
Mesoblast Limited has announced the appointment of Dr Ben-Zion Weiner, Special Adviser to the CEO of Teva Pharmaceutical Industries Ltd, as a non-executive Director of Mesoblast, effective immediately.
Dr Weiner has been Teva’s head of global research and development for over three decades, most recently as Chief R&D Officer and a member of the Teva Executive Committee.
In this role, he has directly overseen all pharmaceutical R&D and innovative branded product pipeline development.
Dr Weiner has been responsible for the development of hundreds of generic products for the US, EU and other markets. In parallel, he has been responsible for the development and regulatory approval of Teva’s innovative product portfolio.
Dr Weiner has twice been the recipient of the Rothschild prize for innovation, including for the commercialization of Copaxone in the treatment of multiple sclerosis.
Dr Weiner said: “I am happy and proud to be a Board member of Mesoblast. I trust that stem cell technology is the future of medicine, and that Mesoblast is at the cutting edge of this exciting new field.
“I believe that Mesoblast’s unique technology and professional execution capabilities have the potential to deliver multiple innovative biologic products across a broad range of clinical indications,” added Dr Weiner.
Mesoblast Chairman, Mr Brian Jamieson, said: “Dr Weiner’s extensive pharmaceutical industry experience and his current role as Special Adviser to the Teva CEO make him a very valuable and strategic addition to the Board. We also acknowledge the important contributions and insights provided by Teva’s retiring board representative, Kevin Buchi, and wish him well.
“As Mesoblast expands its clinical product portfolio and approaches product commercialization, we will continue to broaden the mix of skills and international expertise of our Directors to ensure that the Board is in the best position to deliver maximal shareholder value.”
LifeArc Becomes Technology Transfer Partner to London School of Hygiene & Tropical MedicineNews
LifeArc, the medical research charity, has partnered with London School of Hygiene & Tropical Medicine to provide a range of services in technology transfers.READ MORE
Human Pluripotent Stem Cells Successfully 3D PrintedNews
A breakthrough in the 3D-printing of human pluripotent stem cells means scientists are one step closer to being able to 3D print human organs and tissues for transplantation therapy.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018